论文部分内容阅读
为探讨肝癌内分泌治疗的可行性,作者测定肝癌术后患者、正常肝组织及肝癌组织中雌激素受体(ER)和孕激素受体(PR),并对临床肝癌患者试用内分泌治疗以观察疗效。肝癌患者组织中激素受体。作者收集近2年内20例肝癌太后患者,其中1例为2岁幼女患肝母细胞瘤,余均为肝细胞癌,年龄23～72岁(平均59.4岁),男14例,女5例。AFP值:20例中11例高达200mg/ml以上。HB抗原:20例中2例阳性。20例中16例合并肝硬化。ER和PR测定方法是:肝切除1～2小时后,收集肝正常组织和肝癌组织,放置
To investigate the feasibility of endocrine therapy for hepatocellular carcinoma, the authors measured estrogen receptor (ER) and progesterone receptor (PR) in patients with hepatocellular carcinoma, normal liver tissue, and hepatocellular carcinoma, and tried endocrine therapy for clinical liver cancer patients to observe the efficacy. . Hormone receptors in tissues of liver cancer patients. The authors collected 20 cases of postmenopausal liver cancer patients in the past 2 years, including 1 case of 2-year-old girl suffering from hepatoblastoma, and the rest were hepatocellular carcinoma, aged 23 to 72 years (mean 59.4 years), male 14 cases, female 5 cases. AFP values: 11 of the 20 cases were as high as 200 mg/ml or more. HB antigen: 2 out of 20 cases were positive. Among 20 cases, 16 cases had liver cirrhosis. The ER and PR assays are as follows: 1 to 2 hours after liver resection, liver normal tissues and liver cancer tissues are collected and placed.